On the last check Monday, Reviva Pharmaceuticals Holdings Inc. (RVPH) rose 61.97% to $6.90 in the current market.
The Reviva stock closed at $4.32 on Friday. A price range of $4.16 to $4.34 was observed for RVPH stock in that session. On the release of the lead drug candidate’s trial data, RVPH stock is trending upward.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Read More
What the study data has found?
Revivva is the therapeutic company devoted to discovering, developing and commercializing next-generation therapeutics for diseases with great unmet medical need and burden of society, patients and their families. Research at RVPH is primarily focused on neurological, respiratory and metabolic diseases. The RVPH pipeline consists of two drug candidates: RP5063 (brilaroxazine) and RP1208. Both have been discovered in-house.
Today, Reviva Pharmaceuticals announced details of its Phase 2 clinical trial for RP5063 (brilaroxazine), a candidate drug for Acute Schizophrenia.
- RVPH believes that Brilaroxazine modulates and stabilizes the serotonin (5-HT) and dopamine (D) receptors via its unique pharmacology profile against these receptors.
- This research shows Brilaroxazine binds to key serotonin receptors with high affinity.
- With its combination of high affinity and selectivity for target receptors implicated in schizophrenia, Brilaroxazine by RVPH is pharmacologically different from other antipsychotics.
- An RVPH Phase 2 trial was initiated to assess brilaroxazine safety and efficacy in 234 patients with acute exacerbations of schizophrenia.
How the RVPH candidate performed?
The Reviva (RVPH) study concluded that brilaroxazine met its primary endpoint, which was a reduction in the PANSS total score at the end of treatment, compared to the placebo. Also, RVPH’s drug candidate was well tolerated in clinical, lab, and body weight studies, as well as in lipid, glucose, and EKG tests. Statistically significant treatment difference from the placebo resulted in a 20-point decrease in PANSS total scores in RVPH study.
